Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hypoparathyroidism Treatment Market

Hypoparathyroidism Treatment Market Analysis

  • Report ID: GMI8302
  • Published Date: Feb 2024
  • Report Format: PDF

Hypoparathyroidism Treatment Market Analysis

Based on the product type, the global hypoparathyroidism treatment industry is segmented into supplements and parathyroid hormone. The supplements segment is further divided into calcium supplements, vitamin D supplements, and other supplements. The supplements segment garnered USD 888.2 million revenue in the year 2023.

  • The dominance of the segment can be attributed to the well-established safety profile of supplements, ease of availability, and use in conjunction to optimize the overall treatment.
  • Further, these supplements are widely prescribed by healthcare providers and recommended in clinical guidelines for managing the condition.
  • Thus, wide adoption of supplements as a standard treatment in hypoparathyroidism drives the segmental growth.
Hypoparathyroidism Treatment Market, By Route of Administration (2023)

Based on the route of administration, the global hypoparathyroidism treatment market is classified into oral and parenteral. The oral route segment dominated the market and accounted for 66.5% market share in the year 2023.

  • Oral administration is non-invasive, which means it doesn't involve injections or surgical procedures. For individuals with hypoparathyroidism who require long-term treatment, oral route provide a less discomforting and more acceptable option.
  • Additionally, oral medications can be easily formulated to provide accurate and consistent dosages, allowing healthcare providers to prescribe precise amounts tailored to each patient's needs. This accuracy is crucial in managing mineral imbalances in hypoparathyroidism.

Based on distribution channel, the global market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market and is expected to reach USD 1 billion by 2032.

  • High segment growth is primarily fueled by the well-equipped nature of the hospital pharmacies to handle the compounding and dispensing of these specialized medications, ensuring that patients receive the exact formulations prescribed by their healthcare providers.
  • Moreover, hospital pharmacies are staffed by pharmacists with clinical expertise who work closely with healthcare providers to ensure accurate and safe medication management for patients with complex condition of hypoparathyroidism.
  • Further, high volume of patients visiting hospitals, drives the segmental growth of hospital pharmacy segment.
North America Hypoparathyroidism Treatment Market, 2020 – 2032 (USD Million)

North America hypoparathyroidism treatment market is expected to grow at 6.8% CAGR during the analysis period.

  • Presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities, specialized healthcare professionals, and research institutions in the region facilitates early diagnosis and effective treatment of hypoparathyroidism.
  • Furthermore, the region is a hub for pharmaceutical research and development. Several pharmaceutical companies and research institutions are dedicated to developing treatments for rare diseases, including hypoparathyroidism.
  • All these factors together contribute to the dominance of North America in the global hypoparathyroidism market.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size for hypoparathyroidism treatment was valued at USD 1.3 billion in 2023 and is estimated to account for USD 2.4 billion by 2032, driven by the increasing cases of hypo parathyroid disorders and rising number of thoracic surgeries.

The supplements segment garnered USD 888.2 million in 2023 and is set to gain traction by 2032, attributed to the well-established safety profile of supplements, and ease of availability.

North America market for hypoparathyroidism treatment is expected to grow at 6.8% rate during 2024 and 2032, driven by the presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities and specialized healthcare professionals.

Ascendis Pharma A/S, Amgen Inc., BioNTech SE, Bristol-Myers Squibb Company, Entera Bio Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., SK biopharmaceuticals Co., Ltd., Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.

Hypoparathyroidism Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 290
  • Countries covered: 19
  • Pages: 165
 Download Free Sample